Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Clinical Analysis of Bacterial Infection Characteristics in Lymphoma Patients with High-dose Chemotherapy Combined with Autologous Hematopoietic Stem Cell Transplantation-A Single-Centered Retrospective Study

Author(s): Dan-Hui Sun, Di Mei, Xiao-Qin Yao, Yi-Hui Rong and Gui-Qiang Wang*

Volume 27, Issue 8, 2024

Published on: 21 September, 2023

Page: [1149 - 1160] Pages: 12

DOI: 10.2174/1386207326666230915115056

Price: $65

Abstract

Background: High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDT/AHSCT) is used to treat lymphoma. Although AHSCT has made considerable strides and become safer, HDT-AHSCT infection continues to be a leading cause of morbidity and mortality associated with transplantation.

Objective: To characterise pathogenic bacterial infections in HDT/AHSCT-treated lymphoma patients. The prevalence of pathogenic microorganisms and the timing of foci after transplantation, along with bloodstream infection (BSI) risk factors, can help determine the need for empirical antibiotics after AHSCT.

Methods: We retrospectively analyzed 133 lymphoma patients treated by HDT/AHSCT from April 2017 to October 2021 at Peking University International Hospital, Beijing, China. We analyzed their clinical characteristics, microbiological distribution characteristics, and BSI risk factors in detail.

Results: In order, intestinal infection (56 cases), BSI (17 cases), pulmonary (12 cases), upper respiratory tract (5 cases), and perianal (4 cases) were the most common locations of infection after HDT/AHSCT. The infection sites yielded 92 putative pathogenic pathogens, with bacteria predominating (61.96%), fungi (28.26%), viruses (5.43%), and mycoplasma (4.35%). Gram-negative bacteria (GNB) strains outnumbered gram-positive bacteria (GPB) strains (73.68%). Two strains of Escherichia coli produced extended-spectrum β-lactamase (ESBL) and one strain of carbapenem-resistant enterobacteriaceae (CRE). Methicillin-resistant Staphylococcus epidermidis (MRSE) had one strain. BSI was caused by Escherichia coli (82.35%), Intestinal mucositis (23.52%), and catheter-associated infections (11.76%). Age, CD34, pretreatment regimen, antibiotic regimen, and past chemotherapeutic agent lung damage were BSI risk variables in univariate analysis. CD34 and past chemotherapeutic drug lung damage were the primary causes of BSI after HDT/AHSCT for lymphoma.

Conclusion: High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (HDT/AHSCT) is used to treat lymphoma. Although AHSCT has made considerable strides and become safer, HDT-AHSCT infection continues to be a leading cause of morbidity and mortality associated with transplantation.

Keywords: Lymphoma, high-dose chemotherapy, pathogens, bloodstream infection, risk factors, HDT/AHSCT.

« Previous Next »
Graphical Abstract

[1]
Kanate, A.S.; Kumar, A.; Dreger, P.; Dreyling, M.; Le Gouill, S.; Corradini, P.; Bredeson, C.; Fenske, T.S.; Smith, S.M.; Sureda, A.; Moskowitz, A.; Friedberg, J.W.; Inwards, D.J.; Herrera, A.F.; Kharfan-Dabaja, M.A.; Reddy, N.; Montoto, S.; Robinson, S.P.; Abutalib, S.A.; Gisselbrecht, C.; Vose, J.; Gopal, A.; Shadman, M.; Perales, M.A.; Carpenter, P.; Savani, B.N.; Hamadani, M. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol., 2019, 5(5), 715-722.
[http://dx.doi.org/10.1001/jamaoncol.2018.6278] [PMID: 30816957]
[2]
Wisplinghoff, H.; Seifert, H.; Wenzel, R.P.; Edmond, M.B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin. Infect. Dis., 2003, 36(9), 1103-1110.
[http://dx.doi.org/10.1086/374339] [PMID: 12715303]
[3]
Klastersky, J.; Ameye, L.; Maertens, J.; Georgala, A.; Muanza, F.; Aoun, M.; Ferrant, A.; Rapoport, B.; Rolston, K.; Paesmans, M. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents, 2007, 30(S1), 51-59.
[http://dx.doi.org/10.1016/j.ijantimicag.2007.06.012] [PMID: 17689933]
[4]
Gudiol, C.; Bodro, M.; Simonetti, A.; Tubau, F.; González-Barca, E.; Cisnal, M.; Domingo-Domenech, E.; Jiménez, L.; Carratalà, J. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin. Microbiol. Infect., 2013, 19(5), 474-479.
[http://dx.doi.org/10.1111/j.1469-0691.2012.03879.x] [PMID: 22524597]
[5]
Garcia Borrega, J.; Böll, B.; Kochanek, M.; Naendrup, J.H.; Simon, F.; Sieg, N.; Hallek, M.; Borchmann, P.; Holtick, U.; Shimabukuro-Vornhagen, A.; Eichenauer, D.A.; Heger, J.M. Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: A single-center retrospective analysis. Ann. Hematol., 2023, 102(1), 191-197.
[http://dx.doi.org/10.1007/s00277-022-05028-x] [PMID: 36394583]
[6]
Ferreri, A.J.M.; Cwynarski, K.; Pulczynski, E.; Fox, C.P.; Schorb, E.; Celico, C.; Falautano, M.; Nonis, A.; La Rosée, P.; Binder, M.; Fabbri, A.; Ilariucci, F.; Krampera, M.; Roth, A.; Hemmaway, C.; Johnson, P.W.; Linton, K.M.; Pukrop, T.; Gørløv, J.S.; Balzarotti, M.; Hess, G.; Keller, U.; Stilgenbauer, S.; Panse, J.; Tucci, A.; Orsucci, L.; Pisani, F.; Zanni, M.; Krause, S.W.; Schmoll, H.J.; Hertenstein, B.; Rummel, M.; Smith, J.; Thurner, L.; Cabras, G.; Pennese, E.; Ponzoni, M.; Deckert, M.; Politi, L.S.; Finke, J.; Ferranti, A.; Cozens, K.; Burger, E.; Ielmini, N.; Cavalli, F.; Zucca, E.; Illerhaus, G. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36(7), 1870-1878.
[http://dx.doi.org/10.1038/s41375-022-01582-5] [PMID: 35562406]
[7]
Dhakal, B.; Szabo, A.; Chhabra, S.; Hamadani, M.; D’Souza, A.; Usmani, S.Z.; Sieracki, R.; Gyawali, B.; Jackson, J.L.; Asimakopoulos, F.; Hari, P.N. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction. JAMA Oncol., 2018, 4(3), 343-350.
[http://dx.doi.org/10.1001/jamaoncol.2017.4600] [PMID: 29302684]
[8]
Karagiannis, P.; Sänger, L.; Alsdorf, W.; Weisel, K.; Fiedler, W.; Kluge, S.; Wichmann, D.; Bokemeyer, C.; Fuhrmann, V. Intensive care outcomes of patients after high dose chemotherapy and subsequent autologous stem cell transplantation: A retrospective, single centre analysis. Cancers., 2020, 12(6), 1678.
[http://dx.doi.org/10.3390/cancers12061678] [PMID: 32599837]
[9]
Nassar, A.P., Jr; Archanjo, L.V.F.; Ranzani, O.T.; Zampieri, F.G.; Salluh, J.I.F.; Cavalcanti, G.F.R.; Moreira, C.E.N.; Viana, W.N.; Costa, R.; Melo, U.O.; Roderjan, C.N.; Correa, T.D.; de Almeida, S.L.S.; Azevedo, L.C.P.; Maia, M.O.; Cravo, V.S.; Bozza, F.A.; Caruso, P.; Soares, M. Characteristics and outcomes of autologous hematopoietic stem cell transplant recipients admitted to intensive care units: A multicenter study. J. Crit. Care, 2022, 71, 154077.
[http://dx.doi.org/10.1016/j.jcrc.2022.154077] [PMID: 35636348]
[10]
Michel, C.S.; Teschner, D.; Schmidtmann, I.; Theobald, M.; Hauptrock, B.; Wagner-Drouet, E.M.; Radsak, M.P. Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization. Sci. Rep., 2019, 9(1), 19911.
[http://dx.doi.org/10.1038/s41598-019-56322-0] [PMID: 31882648]
[11]
Eyre, T.A.; Barrington, S.F.; Okosun, J. Impact of PET-CT status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplant. Haematologica, 2022, 108(3), 785-796.
[http://dx.doi.org/10.3324/haematol.2021.280287] [PMID: 35586966]
[12]
Wingard, J.R.; Hsu, J.; Hiemenz, J.W. Hematopoietic stem cell transplantation: An overview of infection risks and epidemiology. Hematol. Oncol. Clin. North Am., 2011, 25(1), 101-116.
[http://dx.doi.org/10.1016/j.hoc.2010.11.008] [PMID: 21236393]
[13]
Dropulic, L.K.; Lederman, H.M. Overview of infections in the immunocompromised host. Microbiol. Spectr., 2016, 4(4), 1-15.
[14]
Maschmeyer, G.; Haas, A. The epidemiology and treatment of infections in cancer patients. Int. J. Antimicrob. Agents, 2008, 31(3), 193-197.
[http://dx.doi.org/10.1016/j.ijantimicag.2007.06.014] [PMID: 17703922]
[15]
Safdar, A.; Armstrong, D. Infectious morbidity in critically ill patients with cancer. Crit. Care Clin., 2001, 17(3), 531-570, vii-viii.
[http://dx.doi.org/10.1016/S0749-0704(05)70198-6] [PMID: 11525048]
[16]
Robak, T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev. Anticancer Ther., 2008, 8(7), 1033-1051.
[http://dx.doi.org/10.1586/14737140.8.7.1033] [PMID: 18588450]
[17]
Elter, T.; Vehreschild, J.J.; Gribben, J.; Cornely, O.A.; Engert, A.; Hallek, M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann. Hematol., 2009, 88(2), 121-132.
[http://dx.doi.org/10.1007/s00277-008-0566-9] [PMID: 18682948]
[18]
Zambelli, A.; Montagna, D.; Da Prada, G.A.; Maccario, R.; Zibera, C.; Moretta, A.; Ponchio, L.; Lozza, L.; Baiardi, P.; Maserati, R.; Marone, P.; Della Cuna, G.R. Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients. Anticancer Res., 2002, 22(6B), 3701-3708.
[PMID: 12552979]
[19]
McCann, S.; Schwenkglenks, M.; Bacon, P.; Einsele, H.; D’Addio, A.; Maertens, J.; Niederwieser, D.; Rabitsch, W.; Roosaar, A.; Ruutu, T.; Schouten, H.; Stone, R.; Vorkurka, S.; Quinn, B.; Blijlevens, N. The prospective oral mucositis audit: Relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant., 2009, 43(2), 141-147.
[http://dx.doi.org/10.1038/bmt.2008.299] [PMID: 18776926]
[20]
Carbone, P.P.; Kaplan, H.S.; Musshoff, K.; Smithers, D.W.; Tubiana, M. Report of the committee on hodgkin’s disease staging classification. Cancer Res., 1971, 31(11), 1860-1861.
[PMID: 5121694]
[21]
Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 1982, 5(6), 649-656.
[http://dx.doi.org/10.1097/00000421-198212000-00014] [PMID: 7165009]
[22]
Freifeld, A.G.; Bow, E.J.; Sepkowitz, K.A.; Boeckh, M.J.; Ito, J.I.; Mullen, C.A.; Raad, I.I.; Rolston, K.V.; Young, J.A.H.; Wingard, J.R. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis., 2011, 52(4), e56-e93.
[http://dx.doi.org/10.1093/cid/cir073] [PMID: 21258094]
[23]
Hughes, W.T.; Armstrong, D.; Bodey, G.P.; Bow, E.J.; Brown, A.E.; Calandra, T.; Feld, R.; Pizzo, P.A.; Rolston, K.V.I.; Shenep, J.L.; Young, L.S. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis., 2002, 34(6), 730-751.
[http://dx.doi.org/10.1086/339215] [PMID: 11850858]
[24]
Chinese Medical Association, Haematology Branch, Chinese Physicians Association, Haematologist Branch. Clinical application guidelines for antimicrobial drugs in patients with neutrophil deficiency with fever in China (2020 edition). Zhonghua Xue Ye Xue Za Zhi, 2020, 41(12), 969-978.
[PMID: 33445842]
[25]
Collin, B.A.; Leather, H.L.; Wingard, J.R.; Ramphal, R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin. Infect. Dis., 2001, 33(7), 947-953.
[http://dx.doi.org/10.1086/322604] [PMID: 11528564]
[26]
Ogonek, J.; Kralj Juric, M.; Ghimire, S.; Varanasi, P.R.; Holler, E.; Greinix, H.; Weissinger, E. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front. Immunol., 2016, 7, 507.
[http://dx.doi.org/10.3389/fimmu.2016.00507] [PMID: 27909435]
[27]
Marchesi, F.; Pimpinelli, F.; Di Domenico, E.; Renzi, D.; Gallo, M.; Regazzo, G.; Rizzo, M.; Gumenyuk, S.; Toma, L.; Marino, M.; Cordone, I.; Cantonetti, M.; Liberati, A.; Montanaro, M.; Ceribelli, A.; Prignano, G.; Palombi, F.; Romano, A.; Papa, E.; Pisani, F.; Spadea, A.; Arcese, W.; Ensoli, F.; Mengarelli, A. Association between CMV and invasive fungal infections after autologous stem cell transplant in lymphoproliferative malignancies: Opportunistic partnership or cause-effect relationship? Int. J. Mol. Sci., 2019, 20(6), 1373.
[http://dx.doi.org/10.3390/ijms20061373] [PMID: 30893777]
[28]
Kontoyiannis, D.P.; Marr, K.A.; Park, B.J.; Alexander, B.D.; Anaissie, E.J.; Walsh, T.J.; Ito, J.; Andes, D.R.; Baddley, J.W.; Brown, J.M.; Brumble, L.M.; Freifeld, A.G.; Hadley, S.; Herwaldt, L.A.; Kauffman, C.A.; Knapp, K.; Lyon, G.M.; Morrison, V.A.; Papanicolaou, G.; Patterson, T.F.; Perl, T.M.; Schuster, M.G.; Walker, R.; Wannemuehler, K.A.; Wingard, J.R.; Chiller, T.M.; Pappas, P.G. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin. Infect. Dis., 2010, 50(8), 1091-1100.
[http://dx.doi.org/10.1086/651263] [PMID: 20218877]
[29]
Sharrack, B.; Saccardi, R.; Alexander, T.; Badoglio, M.; Burman, J.; Farge, D.; Greco, R.; Jessop, H.; Kazmi, M.; Kirgizov, K.; Labopin, M.; Mancardi, G.; Martin, R.; Moore, J.; Muraro, P.A.; Rovira, M.; Sormani, M.P.; Snowden, J.A. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant., 2020, 55(2), 283-306.
[http://dx.doi.org/10.1038/s41409-019-0684-0] [PMID: 31558790]
[30]
Kato, H.; Yamamoto, K.; Matsuo, K.; Oki, Y.; Taji, H.; Kuwatsuka, Y.; Seto, M.; Kagami, Y.; Morishima, Y. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: Association with an incremental risk of infectious events. Ann. Oncol., 2010, 21(8), 1699-1705.
[http://dx.doi.org/10.1093/annonc/mdq008] [PMID: 20172906]
[31]
Arango, J.I.; Restrepo, A.; Schneider, D.L.; Callander, N.S.; Ochoa-Bayona, J.L.; Restrepo, M.I.; Bradshaw, P.; Patterson, J.; Freytes, C.O. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant., 2006, 37(5), 517-521.
[http://dx.doi.org/10.1038/sj.bmt.1705269] [PMID: 16435018]
[32]
Teira, P.; Battiwalla, M.; Ramanathan, M.; Barrett, A.J.; Ahn, K.W.; Chen, M.; Green, J.S.; Saad, A.; Antin, J.H.; Savani, B.N.; Lazarus, H.M.; Seftel, M.; Saber, W.; Marks, D.; Aljurf, M.; Norkin, M.; Wingard, J.R.; Lindemans, C.A.; Boeckh, M.; Riches, M.L.; Auletta, J.J. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood, 2016, 127(20), 2427-2438.
[http://dx.doi.org/10.1182/blood-2015-11-679639] [PMID: 26884374]
[33]
Lark, R.L.; McNeil, S.A.; VanderHyde, K.; Noorani, Z.; Uberti, J.; Chenoweth, C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin. Infect. Dis., 2001, 33(3), 338-343.
[http://dx.doi.org/10.1086/322595] [PMID: 11438899]
[34]
Ruescher, T.J.; Sodeifi, A.; Scrivani, S.J.; Kaban, L.B.; Sonis, S.T. The impact of mucositis on? -hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer, 1998, 82(11), 2275-2281.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2275::AID-CNCR25>3.0.CO;2-Q] [PMID: 9610710]
[35]
Bochud, P.Y.; Eggiman, P.; Calandra, T.; Van Melle, G.; Saghafi, L.; Francioli, P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin. Infect. Dis., 1994, 18(1), 25-31.
[http://dx.doi.org/10.1093/clinids/18.1.25] [PMID: 8054434]
[36]
Labarca, J.A.; Leber, A.L.; Kern, V.L.; Territo, M.C.; Brankovic, L.E.; Bruckner, D.A.; Pegues, D.A. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: Role of severe neutropenia and mucositis. Clin. Infect. Dis., 2000, 30(1), 195-197.
[http://dx.doi.org/10.1086/313591] [PMID: 10619754]
[37]
Vollaard, E.J.; Clasener, H.A. Colonization resistance. Antimicrob. Agents Chemother., 1994, 38(3), 409-414.
[http://dx.doi.org/10.1128/AAC.38.3.409] [PMID: 8203832]
[38]
Endt, K.; Stecher, B.; Chaffron, S.; Slack, E.; Tchitchek, N.; Benecke, A.; Van Maele, L.; Sirard, J.C.; Mueller, A.J.; Heikenwalder, M.; Macpherson, A.J.; Strugnell, R.; von Mering, C.; Hardt, W.D. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. PLoS Pathog., 2010, 6(9), e1001097.
[http://dx.doi.org/10.1371/journal.ppat.1001097] [PMID: 20844578]
[39]
Van der Waaij, D.; Berghuis-de, V.J.M.; Lekkerkerk-van der Wees, J.E.C. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J. Hyg., 1971, 69(3), 405-411.
[http://dx.doi.org/10.1017/S0022172400021653] [PMID: 4999450]
[40]
Hu, F.P.; Zhu, D.M.; Wang, F. CHINET 2013 surveillance of bacterial resistance in China. Chin. J. Infect. Chemother., 2014, 14, 369-378.
[41]
Heinz, W.J.; Buchheidt, D.; Christopeit, M.; von Lilienfeld-Toal, M.; Cornely, O.A.; Einsele, H.; Karthaus, M.; Link, H.; Mahlberg, R.; Neumann, S.; Ostermann, H.; Penack, O.; Ruhnke, M.; Sandherr, M.; Schiel, X.; Vehreschild, J.J.; Weissinger, F.; Maschmeyer, G. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann. Hematol., 2017, 96(11), 1775-1792.
[http://dx.doi.org/10.1007/s00277-017-3098-3] [PMID: 28856437]
[42]
Kwon, J.C.; Kim, S.H.; Choi, J.K.; Cho, S.Y.; Park, Y.J.; Park, S.H.; Choi, S.M.; Lee, D.G.; Choi, J.H.; Yoo, J.H. Epidemiology and clinical features of bloodstream infections in hematology wards: One year experience at the catholic blood and marrow transplantation center. Infect. Chemother., 2013, 45(1), 51-61.
[http://dx.doi.org/10.3947/ic.2013.45.1.51] [PMID: 24265950]
[43]
Wang, F.; Zhu, D.M.; Hu, F.P. 2012 CHINET surveillance of bacterial resistance in China. Chin J Infect Chemother, 2013, 13, 321-330.
[44]
Katsios, C.M.; Burry, L.; Nelson, S.; Jivraj, T.; Lapinsky, S.E.; Wax, R.S.; Christian, M.; Mehta, S.; Bell, C.M.; Morris, A.M. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patients. Crit. Care, 2012, 16(6), R216.
[http://dx.doi.org/10.1186/cc11854] [PMID: 23127353]
[45]
Marr, K.A.; Carter, R.A.; Crippa, F.; Wald, A.; Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis., 2002, 34(7), 909-917.
[http://dx.doi.org/10.1086/339202] [PMID: 11880955]
[46]
Marr, K.A.; Carter, R.A.; Boeckh, M.; Martin, P.; Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood, 2002, 100(13), 4358-4366.
[http://dx.doi.org/10.1182/blood-2002-05-1496] [PMID: 12393425]
[47]
Veeraputhiran, M.; Jain, T.; Deol, A.; Ayash, L.; Kim, S.; Dyson, G.; Bhutani, D.; Lum, L.G.; Ratanatharathorn, V.; Uberti, J.P.; Abidi, M.H. BEAM conditioning regimen has higher toxicity compared with high-dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma. Clin. Lymphoma Myeloma Leuk., 2015, 15(9), 531-535.
[http://dx.doi.org/10.1016/j.clml.2015.05.008] [PMID: 26166312]
[48]
Yoon, D.H.; Sohn, B.S.; Jang, G.; Kim, E.K.; Kang, B.W.; Kim, C.; Kim, J.E.; Kim, S.; Lee, D.H.; Lee, J.S.; Park, S.J.; Park, C.J.; Huh, J.; Suh, C. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion, 2009, 49(9), 1890-1900.
[http://dx.doi.org/10.1111/j.1537-2995.2009.02202.x] [PMID: 19453991]
[49]
Mikulska, M.; Del Bono, V.; Bruzzi, P.; Raiola, A.M.; Gualandi, F.; Van Lint, M.T.; Bacigalupo, A.; Viscoli, C. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection, 2012, 40(3), 271-278.
[http://dx.doi.org/10.1007/s15010-011-0229-y] [PMID: 22187340]
[50]
Scott, B.L.; Park, J.Y.; Deeg, H.J.; Marr, K.A.; Boeckh, M.; Chauncey, T.R.; Appelbaum, F.R.; Storb, R.; Storer, B.E. Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol. Blood Marrow Transplant., 2008, 14(7), 799-806.
[http://dx.doi.org/10.1016/j.bbmt.2008.04.011] [PMID: 18541200]
[51]
Singh, R.K.; Kumar, S.; Prasad, D.N.; Bhardwaj, T.R. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives. Eur. J. Med. Chem., 2018, 151, 401-433.
[http://dx.doi.org/10.1016/j.ejmech.2018.04.001] [PMID: 29649739]
[52]
Reece, D.E.; Nevill, T.J.; Sayegh, A.; Spinelli, J.J.; Brockington, D.A.; Barnett, M.J.; Klingemann, H-G.; Connors, J.M.; Nantel, S.H.; Shepherd, J.D.; Sutherland, H.J.; Voss, N.J.S.; Fairey, R.N.; O’Reilly, S.E.; Phillips, G.L. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant., 1999, 23(11), 1131-1138.
[http://dx.doi.org/10.1038/sj.bmt.1701790] [PMID: 10382952]
[53]
Benekli, M.; Smiley, S.L.; Younis, T.; Czuczman, M.S.; Hernandez-Ilizaliturri, F.; Bambach, B.; Battiwalla, M.; Padmanabhan, S.; McCarthy, P.L., Jr; Hahn, T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant., 2008, 41(7), 613-619.
[http://dx.doi.org/10.1038/sj.bmt.1705951] [PMID: 18071290]

Rights & Permissions Print Cite
Article Metrics
17
2
© 2024 Bentham Science Publishers | Privacy Policy